Abstract
1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in 15 healthy subjects after an intravenous infusion of 50 mg, an intramuscular injection of 100 mg and after administration of two immediate release capsules (A and B), each of 100 mg, in a cross-over study. The effect of the different remoxipride formulations on plasma prolactin concentrations was also studied. 2. The volume of distribution of remoxipride was 0.65 +/- 0.11 kg-1 (mean +/- s.d.). Total plasma clearance was 119 +/- 39 ml min-1, of which 31 +/- 13 ml min-1 was due to renal clearance. The absolute bioavailability after the i.m. and oral formulations was greater than 90%, indicating a small extent of first-pass metabolism. The mean elimination half-life was 4.8 +/- 1.4 h. The unbound fraction of remoxipride and the blood/plasma ratio were 0.19 +/- 0.03 and 0.64 +/- 0.06, respectively. 3. The transient increase in plasma prolactin was similar after all four remoxipride administrations and independent of the given dose.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Farde L., Grind M., Nilsson M. I., Ogenstad S., Sedvall G. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Psychopharmacology (Berl) 1988;95(2):157–161. doi: 10.1007/BF00174501. [DOI] [PubMed] [Google Scholar]
- Frantz A. G. Prolactin. N Engl J Med. 1978 Jan 26;298(4):201–207. doi: 10.1056/NEJM197801262980408. [DOI] [PubMed] [Google Scholar]
- Grind M., Nilsson M. I., Nilsson L., Oxenstierna G., Sedvall G., Wahlén A. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers. Psychopharmacology (Berl) 1989;98(3):304–309. doi: 10.1007/BF00451679. [DOI] [PubMed] [Google Scholar]
- Lapierre Y. D., Nair N. P., Chouinard G., Awad A. G., Saxena B., Jones B., McClure D. J., Bakish D., Max P., Manchanda R. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl. 1990;358:72–77. doi: 10.1111/j.1600-0447.1990.tb05293.x. [DOI] [PubMed] [Google Scholar]
- Lewander T., Westerbergh S. E., Morrison D. Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand Suppl. 1990;358:92–98. doi: 10.1111/j.1600-0447.1990.tb05297.x. [DOI] [PubMed] [Google Scholar]
- Morrison D., Englund A., Lawrie V., Lewander T., Schlachet A., Westerbergh S. E. Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. Acta Psychiatr Scand Suppl. 1990;358:164–169. doi: 10.1111/j.1600-0447.1990.tb05311.x. [DOI] [PubMed] [Google Scholar]
- Müller E. E., Locatelli V., Cella S., Peñalva A., Novelli A., Cocchi D. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983 Apr;25(4):399–432. doi: 10.2165/00003495-198325040-00004. [DOI] [PubMed] [Google Scholar]
- Nilsson L. B. Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J Chromatogr. 1990 Mar 16;526(1):139–150. doi: 10.1016/s0378-4347(00)82491-3. [DOI] [PubMed] [Google Scholar]
- Ogren S. O., Hall H., Köhler C., Magnusson O., Lindbom L. O., Angeby K., Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459–474. doi: 10.1016/0014-2999(84)90567-3. [DOI] [PubMed] [Google Scholar]
- Tench D., Soni S. D., Ashwood T., Movin G. Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia. Psychopharmacology (Berl) 1990;101(1):132–136. doi: 10.1007/BF02253730. [DOI] [PubMed] [Google Scholar]
- Widerlöv E., Termander B., Nilsson M. I. Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man. Eur J Clin Pharmacol. 1989;37(4):359–363. doi: 10.1007/BF00558500. [DOI] [PubMed] [Google Scholar]